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Manifestations Due to Mycoplasma
pneumoniae Infection on the Basis of
Possible Pathogenesis
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Department of Pediatrics, Sapporo Tokushukai Hospital, Sapporo, Japan
The list of extrapulmonary manifestations due toMycoplasma pneumoniae infection can
be classified according to the following three possible mechanisms derived from the
established biological activity of M. pneumoniae; (1) a direct type in which the bacterium
is present at the site of inflammation and local inflammatory cytokines induced by the
bacterium play an important role (2) an indirect type in which the bacterium is not
present at the site of inflammation and immune modulations, such as autoimmunity
or formation of immune complexes, play an important role, and (3) a vascular
occlusion type in which obstruction of blood flow induced either directly or indirectly
by the bacterium plays an important role. Recent studies concerning extrapulmonary
manifestations have prompted the author to upgrade the list, including cardiac
and aortic thrombi as cardiovascular manifestations; erythema nodosum, cutaneous
leukocytoclastic vasculitis, and subcorneal pustular dermatosis as dermatological
manifestations; acute cerebellar ataxia, opsoclonus-myoclonus syndrome, and thalamic
necrosis as neurological manifestations; pulmonary embolism as a respiratory system
manifestation; and renal artery embolism as a urogenital tract manifestation. Continuing
nosological confusion on M. pneumoniae–induced mucositis (without skin lesions),
which may be called M. pneumoniae-associated mucositis or M. pneumoniae-induced
rash and mucositis separately from Stevens-Johnson syndrome, is argued in the
dermatological manifestations. Serological methods are recommended for diagnosis
because pneumonia or respiratory symptoms are often minimal or even absent in
extrapulmonary manifestations due to M. pneumoniae infection. Concomitant use
of immunomodulators, such as corticosteroids or immunoglobulins with antibiotics
effective against M. pneumoniae, can be considered as treatment modalities for most
severe cases, such as encephalitis. Further studies would be necessary to construct
a comprehensive therapeutic strategy, covering microbiology (antibiotics), immunology
(immunomodulators), and hematology (anticoagulants). The possible influence of the
emergence of macrolide-resistant M. pneumoniae on extrapulmonary manifestations,
which can be considered of limited clinical threat in Japan where the resistant rate has
currently decreased, is discussed on the basis of unique biological characteristics of
M. pneumoniae, the smallest self-replicating organism.
Keywords: pneumonia, cytokine, interleukin-18, autoimmunity, immune complex, vasculitis, vasculopathy,
macrolide resistance
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INTRODUCTION
Mycoplasma pneumoniae has been known to cause a wide
variety of extrapulmonary diseases, including several organs
of the human body, but its pathomechanisms remain largely
unknown. Following is a list of extrapulmonary manifestations
due to M. pneumoniae infection classified according to the
three possible pathomechanisms: (1) a direct type in which
the bacterium is present at the site of inflammation and local
inflammatory cytokines induced by the bacterium play an
important role (2) an indirect type in which the bacterium
is not present at the site of inflammation and immune
modulations, such as autoimmunity or formation of immune
complexes, play an important role (3) a vascular occlusion
type in which obstruction of blood flow induced either
directly or indirectly by the bacterium plays an important
role (Narita, 2009, 2010, 2011a). Several years have passed
since the initial list was presented and recent studies have
prompted the author to upgrade the list (Table 1). While
constructing the list, according to the primary policy (Narita,
2009, 2010, 2011a), diseases that can reasonably be considered
true extrapulmonary manifestations due to M. pneumoniae
infection on the basis of established biological ability of
M. pneumoniae were preferentially selected, although it is hard
to prove exactly the causal relation between M. pneumoniae
infection and the development of diseases in indirect type
manifestations. Because more recent studies are preferentially
cited in this review, many fundamentally important matters
are not mentioned here; frequent absence of pneumonia in the
direct type manifestations, cold agglutinins in hematological
manifestations, autoantibodies in neurological manifestations,
and immunodeficiency in arthritis, among others. Also refer
to the previous reviews (Narita, 2009, 2010, 2011a) for further
discussions on those matters.
Cardiovascular System Manifestations
Cardiac thrombi in the left atrium (Bakshi et al., 2006), in the
right ventricle (Nagashima et al., 2010), and an aortic thrombus
(Flateau et al., 2013) have been reported as the vascular occlusion
type manifestation of the cardiovascular system. Interestingly, all
the cases revealed the existence of some type of antiphospholipid
antibodies in the blood, such as anticardiolipin antibody and
lupus anticoagulant, which can be raised during M. pneumoniae
infection through molecular mimicry between M. pneumoniae
cell components and human phospholipids (Narita, 2011a). A
mechanism speculating about how these antibodies modulate
the coagulation system leading to thrombosis is incompletely
understood. These antibodies in most cases disappear during
convalescence and the hypercoagulable state does not last for
many months. Pneumonia may or may not be present. A short
comprehensive review on this topic is presented in (Flateau et al.,
2013).
While Kawasaki disease associated with M. pneumoniae
infection is not unusual in Japan (Narita, 2010, 2011a) andmay be
found in Korea (Lee et al., 2011), the disease association is rarely
reported outside Asia; however, few recent cases were observed
in Italy (Vitale et al., 2010) and the United States (Ebrahim
et al., 2011). Considering that pneumonia is not a hallmark
of mycoplasmal infection, further surveys outside Asia would
more precisely delineate the occurrence of this disease association
among different ethnic groups. A short analytical review on this
topic can be found in (Lee et al., 2011).
A recent report from China on myocardial damages during
M. pneumoniae infection presented a little evidence for some type
of immune modulation byM. pneumoniae (Fan et al., 2015).
Dermatological Manifestations
Erythema nodosum, which is considered to be an immune-
mediated disease, mainly affects young women (<30 years
old) and is characterized clinically by tender erythematous
nodules (diameter > 1 cm) on lower legs and histologically by
septal panniculitis (Cribier et al., 1998; Kakourou et al., 2001).
While its frequency among mycoplasmal infections has been
reported to be rather small, that is, in 3/27 (11%) patients
with established etiology (Kakourou et al., 2001) or 1/32 (3.1%)
patients undergoing mycoplasmal serology testing (Cribier et al.,
1998), increasing awareness of the disease association (Kano
et al., 2007; Schalock and Dinulos, 2009; Shimizu et al., 2012)
allows it to become a subject of specific reviews (Greco et al.,
2015; Terraneo et al., 2015). This disease must be included in
the indirect type manifestations. Pneumonia is infrequent in this
disease.
Cutaneous leukocytoclastic vasculitis is a pathological
entity of skin disease characterized histologically by a
neutrophilic perivascular infiltrate and clinically by erythematous
macropapular rash mainly on lower extremities; it resembles
erythema nodosum but is less tender and smaller in size
(Kakourou et al., 2001). Several cases of this disease have
been reported in association with M. pneumoniae infection
(Van Bever et al., 1992; Perez et al., 1997; Perez and Montes,
2002; Greco et al., 2007; Trcˇko et al., 2012; Lee et al., 2015;
Terraneo et al., 2015). Interestingly the reported cases were
almost always accompanied by other organ involvement such
as glomerulonephritis (Lee et al., 2015), arthritis (Perez et al.,
1997; Lee et al., 2015), or arthralgia (Trcˇko et al., 2012), retinal
vasculitis (Greco et al., 2007), encephalitis (Perez and Montes,
2002), and acute respiratory distress syndrome, erythema
multiforme, and pancreatitis (Van Bever et al., 1992). Because
circulating immune complexes are considered to play a critical
role in the pathogenesis of cutaneous leukocytoclastic vasculitis
(Van Bever et al., 1992; Perez and Montes, 2002; Trcˇko et al.,
2012), this must be a partial manifestation of systemic vasculitic
disease as a consequence of immune dysregulation elicited by
an M. pneumoniae infection. Pneumonia may or may not be
present.
Nosological confusion still exists concerning the spectrum of
skin and mucous membrane diseases, including Stevens-Johnson
syndrome (SJS), Fuchs syndrome, toxic epidermal necrolysis,
and erythema multiforme major (Schalock and Dinulos, 2009;
Wetter and Camilleri, 2010; Kunimi et al., 2011; Meyer Sauteur
et al., 2012; Canavan et al., 2015a; Vujic et al., 2015). It has
been acknowledged that M. pneumoniae is the most frequent
infectious agent identified in “typical SJS” (Schalock and Dinulos,
2009;Wetter and Camilleri, 2010; Kunimi et al., 2011), presenting
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TABLE 1 | Extrapulmonary manifestations due to M. pneumoniae infection classified according to the involved pathomechanisms.
Manifestations Direct typea Indirect typeb Vascular occlusion
typec
Undeterminedd
Cardiovascular system Pericarditis,
Endocarditis
Myocarditis, Kawasaki disease Cardiac thrombus,
Aortic thrombus
Dermatological Erythema multiforme, Urticaria,
Anaphylactoid purpura, EN, CLV,
SJS, MPAM, SPD
Digestive organ Early onset
hepatitis
Late onset hepatitis Pancreatitis
Hematological/
Hematopoietic system
Autoimmune hemolytic anemia,
Hemophagocytic syndrome,
Thrombocytopenic purpura,
Infectious mononucleosis
Disseminated
intravascular
coagulation, Splenic
infarct
Musculoskeletal
system
Arthritis Rhabdomyolysis
Neurological Early onset
encephalitis, Early
onset myelitis,
Aseptic
meningitis
Late onset encephalitis, Late onset
myelitis, Guillain-Barré syndrome,
Cranial/peripheral neuropathies,
Cerebellitis, Acute cerebellar ataxia,
Opsoclonus-myoclonus syndrome
Stroke, Psychological
disorders, Striatal
necrosis, Thalamic
necrosis
Acute
disseminated
encephalomyelitis
Respiratory system Pulmonary embolism
Sensory organ Otitis media Conjunctivitis, Iritis, Uveitis Sudden hearing loss
Urogenital tract Glomerulonephritis, IgA nephropathy Priapism,
Renal artery embolism
aM. pneumoniae causes inflammation at the local site through the induction of cytokines.
bM. pneumoniae causes inflammation through immune modulation such as autoimmunity, or formation of immune complexes.
cM. pneumoniae causes vasculitic and/or thrombotic vascular occlusion with or without systemic hypercoagulable state.
dEither or all of the above three types of mechanisms may be involved.
Underlines indicate diseases which are newly included in the panel or grouped into a different type of manifestation from the previous list (Narita, 2010).
EN, erythema nodosum; CLV, cutaneous leukocytoclastic vasculitis; SJS, Stevens-Johnson syndrome; MPAM, Mycoplasma pneumoniae-associated mucositis; SPD, Subcorneal
pustular dermatosis.
with fever, conjunctivitis, stomatitis, generalized, often bullous
cutaneous lesions (macules and flat atypical target lesions)
involving <10% of body surface, and severe morbidity and
substantial mortality (Meyer Sauteur et al., 2012). Moreover,
an outbreak of M. pneumoniae-associated “typical SJS” was
recently reported (Olson et al., 2015). In parallel with this,
presence of another distinct form of diseases mimicking SJS and
without skin lesions, is widely noticed and is often called as
“atypical SJS” or “incomplete SJS.” Although universal agreement
has not yet been established, those can be a distinct entity
and are presently called M. pneumoniae-associated mucositis
(Schalock and Dinulos, 2009; Meyer Sauteur et al., 2012; Vujic
et al., 2015) or M. pneumoniae-induced rash and mucositis
(Canavan et al., 2015a,b; Norton, 2015). From a clinical point
of view, M. pneumoniae-associated mucous membrane diseases,
irrespective of whether they are “typical” or “atypical,” have
been considered less severe, often sensitive to corticosteroid
therapy, and with fundamentally good prognosis when compared
with drug-induced diseases (Schalock and Dinulos, 2009; Wetter
and Camilleri, 2010; Kunimi et al., 2011; Meyer Sauteur et al.,
2012; Canavan et al., 2015a; Vujic et al., 2015). These factors
may be important especially for physicians in treating this
spectrum of diseases, because to distinguish M. pneumoniae-
associated diseases from drug-induced diseases early in the
course allows them to predict the better prognosis for the
M. pneumoniae-associated diseases. One factor which favors
the M. pneumoniae-associated rather than the drug-induced
diseases is younger age as it occurs more often in children
and younger adults (Wetter and Camilleri, 2010; Kunimi et al.,
2011; Canavan et al., 2015b; Norton, 2015). Meanwhile, three
independent reports have similarly pointed out that severe ocular
lesions were fairly frequent in the M. pneumoniae-associated
diseases compared to the drug-induced diseases (Wetter and
Camilleri, 2010; Kunimi et al., 2011; Olson et al., 2015),
and might be an additional diagnostic indicator. Regarding
pathogenesis, immunological mechanisms such as autoimmunity
and immune complex-mediated vascular injury have been
suspected irrespective of whether it isM. pneumoniae-associated
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or not. Some authors have speculated that the synergistic effects
ofM. pneumoniae infection (and ensuing immune dysregulation)
and drug exposure are important factors in developing mucous
lesions (Schalock and Dinulos, 2009; Shimizu et al., 2012; Kurata
et al., 2016). The reason why the M. pneumoniae-associated
lesions are confined to the mucous membranes remains unclear.
Lastly, the fact thatM. pneumoniae was isolated from skin blister
fluid on at least two independent occasions must not be ignored,
which suggests the possibility of a direct type mechanism (Lyell
et al., 1967; Meseguer et al., 1986). Because M. pneumoniae can
never infect squamous cell epithelium, hematogenous transfer
of M. pneumoniae from the respiratory tract to the skin might
generate the inflammatory bullous lesions through the induction
of cytokines.
Although very rare, subcorneal pustular dermatosis must
be associated with M. pneumoniae infection (Lombart, 2014;
Bohelay et al., 2015), which can be considered an indirect
manifestation.
Digestive Organ Manifestations
A report on liver dysfunction in adults further substantiated the
premise that hepatitis can be grouped into the two categories,
consisting of the early- and late-onset types, the former being
reported to occur at a median of 4 days from the respiratory
onset and the latter at 13 days (Shin et al., 2012). Molecular
mimicry between mycoplasmal cell components and sialo-
oligosaccharides displayed on hepatic cell surfaces was speculated
as a pathomechanism for the late-onset type. Another recent
report on hepatic damages during M. pneumoniae infection also
presented a little evidence for some type of immune modulation
byM. pneumoniae (Fan et al., 2015).
A case report on necrotizing pancreatitis (Yang et al., 2015)
favors vascular occlusion as the etiology of acute pancreatitis
associated withM. pneumoniae infection as previously suggested
(Van Bever et al., 1992; Narita, 2010).
Hematological/Hematopoietic System
Manifestations
A case of splenic artery embolism was reported as a vascular
occlusion type manifestation (Flateau et al., 2013).
Musculoskeletal System Manifestations
We have reported that production of tumor necrosis factor-
α might play a role in the pathogenesis of rhabdomyolysis
associated withM. pneumoniae infection (Oishi et al., 2012).
Neurological Manifestations
Opsoclonus-myoclonus syndrome is a rare neurological disorder
characterized by involuntary, irregular, and multidirectional eye
movements with myoclonus predominantly affecting the head
and trunk and signs of cerebellar ataxia, especially the inability
to stand and walk. While this syndrome has been known to
occur in association with neuroblastomas in infants between 6
and 36 months and with various types of malignant tumors in
adults, infectious etiologies are also known. Recent studies on
this syndrome in association with M. pneumoniae infection in
children (Huber et al., 2010; Shiihara and Takahashi, 2010) as
well as in adults (Mesraoua et al., 2011; Nunes et al., 2011), which
have suggested immune pathogenesis, have made it reasonable to
assume that this syndrome can be included in the indirect type
manifestations.
In addition to striatal necrosis (Narita, 2009, 2011a), brain
diseases, in which characteristic bilateral lesions are observed on
neuroimaging, have not infrequently been reported in association
with M. pneumoniae infection. The affected areas include the
pons (Perez and Montes, 2002), thalamus (Ashtekar et al.,
2003), basal ganglia, and thalamus (Fusco et al., 2010), striatum
and brain stem (Bae et al., 2011), and splenium of corpus
callosum (Shibuya et al., 2012). Vasculitic necrosis is considered
a presumptive etiology in some (Perez and Montes, 2002;
Ashtekar et al., 2003), and immune pathogenesis is considered
in others (Fusco et al., 2010; Bae et al., 2011). In this context,
the clinical picture of a case presented in Perez and Montes
(2002) fairly resembles that of acute necrotizing encephalopathy,
which favors vasculitic etiology (Narita, 2002), whereas the
intrathecal production of interleukins-6 and -8 was found in the
patients with striatal necrosis (Yuan et al., 2015), as reported
in the cases of encephalitis (Narita et al., 2005), which favors
immune pathogenesis. A recent comprehensive study suggested
that these manifestations are not peculiar but is a common form
of encephalitis in children (Al-Zaidy et al., 2015). Representative
of these diseases, both striatal and thalamic necrosis are included
in the list of this review as vascular occlusion type manifestations.
Meanwhile, some nosological alterations might be necessary
concerning the use of the term “necrosis” for the fundamentally
benign, reversible lesions, which are a characteristic of M.
pneumoniae infection (Fusco et al., 2010).
Concerning disseminated encephalomyelitis, a recent paper
reported that the genome of M. pneumoniae was detected
in cerebrospinal fluid, suggesting the direct type mechanism
(Matsumoto et al., 2009), whereas another paper reported a
dramatic improvement after plasma exchange, suggesting the
indirect type mechanism leading to vasculopathy (Gupta et al.,
2009). The aforementioned study has suggested that a single
etiology cannot explain the pathogenesis of acute disseminated
encephalomyelitis (Al-Zaidy et al., 2015). In addition, the study
also suggested that the classification for encephalitis can also be
applied to transverse myelitis (the early onset, direct type or the
late onset, indirect type).
Two cases of transient Parkinsonism in association with
M. pneumoniae infections have recently been reported (Tay et al.,
2014). With more attention given to M. pneumoniae infections
even in the absence of respiratory symptoms, more cases
of M. pneumoniae infection-associated psychological disorders
would be diagnosed especially when it is transient and occurs in
children or young adults.
Cerebellitis has been constantly reported as part of a disease
involving multiple parts of the brain (Christo et al., 2010;
Bae et al., 2011; Meyer Sauteur et al., 2014a) or as an
isolated disease (Shkalim et al., 2009; Simpkins et al., 2012;
Schmucker et al., 2014). Immune-mediated pathogenesis has
been advocated for cerebellitis and is most likely an indirect type
manifestation. The fact that lymphocytic infiltration was found
in the cerebellar tissue in the late onset case (Simpkins et al.,
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2012) is of some interest because the neutrophilic infiltration
has typically been found in the cerebral tissues of early onset
cases (Bruch et al., 2001; Stamm et al., 2008). Implication
of these observations on pathogenesis remains unclear, but
accumulation of histological investigations should provide us
with clues for further understanding of the pathogenesis of
neurological manifestations.
In acute cerebellar ataxia the evidence of neural inflammation
is apparently absent and an immune-mediated pathogenesis has
been suggested (Cimolai et al., 1994); this has been added to the
list separately from cerebellitis.
Although it is still premature to conclude that it is a true
manifestation of M. pneumoniae infection, a peculiar and rather
pathologically identified disease entity called “mycoplasmal
cerebral vasculopathy” has recently been suggested (Zu-Rhein
et al., 2007; Ferreira, 2011; Rhodes et al., 2011). Because of
its slowly progressive clinical course that occurs over several
years with episodic encephalopathy and movement disorders, it
is hard to determine whether the disease constitutes a distinct
clinical entity. Nevertheless, the findings that M. pneumoniae
antigens were found in the cytoplasm of brain microvascular
endothelial cells as well as inmicrovascular lumina by histological
investigations are highly interesting. This appears to further
support the ability of hematogenous transfer of M. pneumoniae
to the brain and to elicit vasculitis or vasculopathy at those local
sites.
At the end of this section, a schematic presentation is
shown in Figure 1 for the neurological manifestations due to
M. pneumoniae infection classified according to the possible
pathomechanisms, which can be perplexing and sometimes
overlapping. This figure suggests one possibility and is amenable
to improvement by future studies. More information on
neurological manifestations is presented in recent studies (Bitnun
and Richardson, 2010; Meyer Sauteur et al., 2014b).
Respiratory System Manifestations
A few cases of pulmonary embolism have been reported in
association withM. pneumoniae infection (Sterner and Biberfeld,
1969; Brown et al., 2008; Graw-Panzer et al., 2009). Production of
antiphospholipid antibodies has been shown to be an underlying
mechanism for thrombus formation (Brown et al., 2008; Graw-
Panzer et al., 2009).
Urogenital Tract Manifestations
Each case of glomerulonephritis (Shimizu et al., 2012) or
glomerulonephritis with interstitial nephritis (Lee et al., 2015)
was recently reported along with multiple skin lesions mentioned
in the previous dermatological section. The genome of M.
pneumoniae was detected by polymerase chain reaction in a
serum sample from a patient with glomerulonephritis (Chen
et al., 2015), which further substantiated the assumption that
circulating immune complexes containing mycoplasmal cell
components are probably involved in the pathogenesis.
A case of renal artery embolism was reported in a patient with
multiple embolisms (Flateau et al., 2013).
A new case of pediatric priapism was recently reported
(Jacobs et al., 2015), which substantiated that this condition
FIGURE 1 | Schematic presentation of neurological manifestations due
to M. pneumoniae infection classified according to the possible
pathomechanisms. Cytokines involving interleukin-6 and interleukin-8,
among others. Vasculitis, thrombosis, vasculopathy, and embolism involving
formation of immune complexes, production of antiphospholipid antibodies,
among others. Autoimmunity involving molecular mimicry between
mycoplasmal cell components and gangliosides, and galactocerebrosides,
among others. These mechanisms are not mutually exclusive and can
concomitantly work in a patient resulting in perplexed clinical features of
neurological manifestations.
can be an extremely rare but reasonable vascular occlusion type
manifestation.
DIAGNOSIS OF EXTRAPULMONARY
MANIFESTATIONS DUE TO M. pneumoniae
INFECTIONS
Since the primary site of infection and subsequent propagation
of M. pneumoniae is restricted to the ciliated epithelium of
the lower respiratory tract, any existing bacterial cells cannot
be transferred to the upper respiratory tract in the absence
of strong cough. In this context, as repeatedly mentioned in
this and the previous reviews (Narita, 2009, 2010, 2011a),
extrapulmonary manifestations due to M. pneumoniae infection
often occur in the absence of pneumonia or even in the
absence of respiratory symptoms. For this reason, molecular
detection or culture methods using routine clinical samples
obtained from the upper respiratory tract (such as pharyngeal
swabs) are not always adequate for diagnosing extrapulmonary
manifestations. Therefore, the diagnosis should be done by
serological methods, which usually requires obtaining a second
serum sample. On a few special occasions, molecular detection
methods may be applied for non-respiratory samples, such as
cerebrospinal fluid for encephalitis. For cases with abundant
cough, point-of-care tests, which have recently been developed
in Japan and include the loop-mediated isothermal amplification
method (Kakuya et al., 2014; Petrone et al., 2015) or the antigen
detection method (Miyashita et al., 2015b), should be used
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because they may help in rapid diagnosis during the acute
phase.
TREATMENT OF EXTRAPULMONARY
MANIFESTATIONS DUE TO M. pneumoniae
INFECTION
There is no doubt that aberrant host immune responses
play a critical role in the development of extrapulmonary
manifestations due to M. pneumoniae infections.
Therefore, immunomodulators, such as corticosteroids or
immunoglobulins, should be beneficial for the most severe
cases, such as encephalitis or SJS. Moreover, anticoagulation
therapy should be highly promising for the vascular occlusion
type manifestations. In any of the cases, antibiotics effective
against M. pneumoniae must be used concomitantly to
reduce the amount of M. pneumoniae cells in the respiratory
tract; this consequently results in the reduction of excessive
antigenic stimuli. Larger studies would be necessary to
construct the comprehensive therapeutic strategy covering
microbiology (antibiotics), immunology (immunomodulators),
and hematology (anticoagulants).
POSSIBLE INFLUENCE OF THE
EMERGENCE OF MACROLIDE-RESISTANT
M. pneumoniae ON EXTRAPULMONARY
MANIFESTATIONS
Since 2000, when the first case of pneumonia due to macrolide-
resistant M. pneumoniae was diagnosed in Japan (Okazaki et al.,
2001), macrolide resistance has grown to be a significant problem
in some countries, particularly in eastern Asia. A few cases
of extrapulmonary manifestations due to macrolide-resistant
M. pneumoniae have been reported (Atkinson et al., 2011; Koga
et al., 2012; Oishi et al., 2012; Shen et al., 2013; Zhou et al., 2014).
While the studies from China have reported that a substantial
number of complications (most frequently liver and myocardial
dysfunctions) occurred in patients infected by resistant strains
(Shen et al., 2013; Zhou et al., 2014), no appreciable increase in
the number of extrapulmonary manifestations has been observed
in Japan in conjunction with a significant increase in the number
of pneumonia patients infected by the resistant strains. This
must be in part due to the impairment of the growth ability
of resistant strains of M. pneumoniae when compared with
the sensitive strains (Ohya et al., 2009, 2010; Pauchant et al.,
2009) Some reasons for this are described in the following
paragraphs.
M. pneumoniae is one of the smallest self-replicating
organisms and has many peculiar biological characteristics.
First of all, the most important characteristic associated with
drug resistance is that extrinsic genes, such as plasmids or
transposons, do not function within M. pneumoniae cells under
natural conditions (Bébéar and Pereyre, 2005). Consequently, the
resistant mechanism of M. pneumoniae is exclusively due to a
point mutation in the domain V of 23S rRNA. Second, since
M. pneumoniae has only one operon for constructing ribosomes
(Himmelreich et al., 1996), the resistant strains that harbor
a point mutation within their ribosome genes are exclusively
mutants of ribosomes. Therefore, they suffer from less efficient
protein synthesis and are deficient in growth ability (Narita,
2011b). In fact, no excessive morbidity has been observed
particularly ascribed to the drug resistance in the reported cases
(Atkinson et al., 2011; Koga et al., 2012; Oishi et al., 2012).
In addition to that, serum levels of IL-18, which represent
disease activity of M. pneumoniae infection (Narita et al., 2000;
Tanaka et al., 2002; Oishi et al., 2011; Miyashita et al., 2015a),
were rather lower in patients with pneumonia infected by
the resistant strains than in patients infected by the sensitive
strains (Matsuda et al., 2013). Taken together, the emergence
of macrolide-resistant M. pneumoniae must not be a significant
clinical threat concerning extrapulmonary manifestations of
M. pneumoniae infection at least in Japan, where the resistant
rate has fundamentally been decreasing according to the current
data obtained from 2013 to 2015 (presented at domestic Japanese
meetings).
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